NVE Corporation NVEC

Set alert

Price alert · NVEC

All alert types
77.58 USD -4.40 -5.37%

At close

78.48 +0.90 +1.16%

Pre-market · Nov 2, 7:39 AM ET

Bid
77.44 × 2
Ask
77.61 × 2
76.41 Day range 80.41
57.21 52-week range 135.00
YTD
+30.76%
1 year
+13.42%
Open
78.90
Prev close
81.98
Mkt cap
375.80M
Vol
116.92K
Avg vol
128.54K
EPS
3.69
P/E
21.02
Div yield
4.88%
More statistics
Low
76.41
High
80.41
Forward P/E
28.59
Beta
1.13
Short ratio
5.61
Inst. own
69.61%
Dividend
4.00
Ex-div date
Nov 3, 2024
Earnings
Jan 15, 2025
50-d avg
78.00
200-d avg
79.04
1y target
0.00

1m chart

Chart tools
Interval

Built from the cached one-day intraday bars.

Signals (32)
NameTimeAgo
SMA: BullishOct 30, 3:59 PM2 days ago
SMA: BullishOct 30, 3:59 PM2 days ago
SMA: BearishOct 30, 3:56 PM2 days ago
SMA: BearishOct 30, 3:56 PM2 days ago
SMA: BullishOct 30, 3:50 PM2 days ago
SMA: BullishOct 30, 3:41 PM2 days ago
SMA: BearishOct 30, 3:37 PM2 days ago
MACD: Buy SignalOct 30, 3:25 PM2 days ago
SMA: BullishOct 30, 3:08 PM2 days ago
RSI: OversoldOct 30, 2:20 PM2 days ago
MACD: Sell SignalOct 30, 2:07 PM2 days ago
SMA: BearishOct 30, 1:59 PM2 days ago
MACD: Buy SignalOct 30, 1:51 PM2 days ago
SMA: BullishOct 30, 1:44 PM2 days ago
SMA: BearishOct 30, 12:30 PM2 days ago
SMA: BearishOct 30, 12:30 PM2 days ago
SMA: BullishOct 30, 12:16 PM2 days ago
SMA: BullishOct 30, 12:16 PM2 days ago
SMA: BearishOct 30, 12:11 PM2 days ago
SMA: BullishOct 30, 12:08 PM2 days ago
SMA: BearishOct 30, 12:01 PM2 days ago
SMA: BullishOct 30, 11:49 AM2 days ago
SMA: BearishOct 30, 11:43 AM2 days ago
SMA: BearishOct 30, 11:17 AM2 days ago
SMA: BullishOct 30, 11:12 AM2 days ago
SMA: BearishOct 30, 11:01 AM2 days ago
SMA: BullishOct 30, 10:56 AM2 days ago
SMA: BearishOct 30, 10:53 AM2 days ago
SMA: BullishOct 30, 10:36 AM2 days ago
SMA: BearishOct 30, 10:27 AM2 days ago
SMA: BullishOct 30, 10:23 AM2 days ago
SMA: BearishOct 30, 10:09 AM2 days ago

Discussion (2)

Sign in to join the discussion

VICKY HANUKA NVEC 3 years ago #1

$PTC Therapeutics(PTCT.US)$ ?????????????? Royalty Pharma Announces Agreement to Purchase Up to $1.5 Billion of PTC Therapeutics' Royalty on Evrysdi -- Royalty Pharma purchases a portion of royalties on Roche's Evrysdi for
$1.0 billion upfront
-- PTC Therapeutics has option to sell rest of royalty for up to $500
million; Royalty Pharma has option to buy half of rest of royalty for up
to $250 million
-- Transaction expected to enhance long-term Adjusted Cash Receipts growth
(non-GAAP)
-- Royalty Pharma to host conference call today, Thursday, October 19 at
9:00am EDT
NEW YORK, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today an agreement with PTC Therapeutics, Inc. to acquire additional royalties on Roche's Evrysdi for $1.0 billion upfront. The agreement includes options for PTC to sell up to all of its retained royalties on Evrysdi for up to $500 million or for Royalty Pharma to acquire half of such retained royalties for up to $250 million at a later date.